Chris Retzler, Needham Growth Fund, and Ronny Gal, Sanford C. Bernstein, discuss buying opportunities amid health care's underperformance. With CNBC's Mike Santoli and Stephanie Link, TIAA Global Asset Management. » Read More
Double-digit percentage increases of drugs have been common since 2011, and quadruple-digit prices have been seen for many cheaper medications. » Read More
Michael Babich, the former CEO of the Arizona-based drug maker, was among five individuals charged in an indictment filed. » Read More
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
Ralph Nader, former presidential candidate and consumer advocate, responds to Mylan and what she had to say about the EpiPen pricing outrage.
CNBC's Jim Cramer fires back Thursday on comments from Mylan about pricing of the auto-injection device EpiPen.
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people — but at the end of the day, its CEO told CNBC she has a business to run.
Shares of Mylan held slightly lower in afternoon trade, giving up earlier gains of more than 4 percent.
Mylan announced plans to boost access to its EpiPen Auto-Injector by expanding programs for patients who are facing higher out-of-pocket costs.
Mylan CEO Heather Bresch speaks to CNBC on Thursday about the controversy surrounding her company's 400-percent price hike to EpiPens over the past few years.
Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one's more frustrated than her.
Under pressure, Mylan plans to boost access to its EpiPen Auto-Injector by expanding existing programs for patients who are facing higher costs.
Regulators should consider how to intervene when there is just one supplier for a specific drug, says Frost & Sullivan's Rhenu Bhuller.
Mylan hiked prices in the midst of heated U.S. elections where both candidates agreed that drug prices are too high, says WBB Securities' Steve Brozak.
Shares of Teva Pharmaceuticals fell as much as 6 percent after the U.S. Patent Office invalidated two of the company's patents.
Umer Raffat, Evercore ISI Senior Analyst, discusses how Mylan's stock price may be affected long-term by the EpiPen pricing saga.
The "Fast Money" traders discuss the effect of Mylan's EpiPen pricing controversy on the biotech sector.
Heather Bresch is the daughter of a U.S. senator, incorporated her American company in the Netherlands and got an MBA she wasn't entitled to.
CNBC's Bob Pisani looks at the day's market action, including a look at which biotech stocks started to fall amid Mylan's EpiPen outrage.
Get the best of CNBC in your inbox